Fig. 4.

bITH is independent of blood tumor mutation burden (bTMB) and superior in predicting overall survival to immune checkpoint blockade therapy in the OAK cohort. (a) Forest plots compare the atezolizumab-over-docetaxel associated overall survival (OS) and progression-free survival (PFS) with bITH and bTMB strata. P (interaction), a p-value of the interaction term indicates the statistical power of predictive efficacy. (b) Merge of Kaplan–Meier curves comparing OS and PFS segregation of bITH and bTMB status among OAK patients receiving atezolizumab. (c) Forest plots illustrating multivariable cox regression model of atezolizumab-associated OS and PFS that include factors with p ≤ 0.1 in univariable Cox regression and immunotherapy-related characteristics like bTMB and PD-L1 positivity. (d) Venn diagram illustrating the overlap between bITH-low and bTMB-high patients. (e) Kaplan–Meier curves comparing OS of four groups stratified with bITH status and treatment among bTMB-low patients. Forest plots of HRs indicating treatment difference of bITH status. Table illustrating median OS, HRs, and corresponding log-rank test p-values.